Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q2 EPS of $0.21, $0.35 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $71.47 million versus the consensus estimate of $52.06 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.